Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bring in conjunction with investment in DreamLogistics
Mandate

Vinge advises Bring in conjunction with investment in DreamLogistics

October 18, 2021 M&A EU, Competition and Regulatory

Vinge has advised Bring in conjunction with its investment in the logtech company DreamLogistics, which is Sweden’s fastest growing 3PL company. The investment is part of Bring’s focus on fulfilment.

The transaction is subject to customary competition approval.

Vinge’s team consisted of, among others, Johan Winnerblad, Johan Karlsson, Desirée Hagenfeldt, Christa Anttila, Sebastian Örndahl, Annie Fällström, Gustav Lindgren and Victoria Fredén.

Related

Vinge advises Aspo on its acquisition of Swed Handling

 Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

 Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

 Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024